Houston Methodist Research Institute nanomedicine researchers used an implantable nanofluidic device smaller than a grain of rice to deliver immunotherapy directly into a pancreatic tumor.
Credit: Houston Methodist
Taming pancreatic cancer with intratumoral immunotherapy
Houston Methodist nanomedicine researchers have found a way to tame pancreatic cancer – one of the most aggressive and difficult to treat cancers – by delivering immunotherapy directly into the tumor with a device that is smaller than a grain of rice.
In a paper recently published in Advanced Science, Houston Methodist Research Institute researchers used an implantable nanofluidic device they invented to deliver CD40 monoclonal antibodies (mAb), a promising immunotherapeutic agent, at a sustained low-dose via the nanofluidic drug-eluting seed (NDES). The result, found in murine models, was tumor reduction at a fourfold lower dosage than traditional systemic immunotherapy treatment.
“One of the most exciting findings was that even though the NDES device was only inserted in one of two tumors in the same animal model, we noted shrinkage in the tumor without the device,” said Corrine Ying Xuan Chua, Ph.D., co-corresponding author and assistant professor of nanomedicine at Houston Methodist Academic Institute. “This means that local treatment with immunotherapy was able to activate the immune response to target other tumors. In fact, one animal model remained tumor-free for the 100-days of continued observation.”
Pancreatic ductal adenocarcinoma is frequently diagnosed at advanced stages. In fact, about 85% of patients already have metastatic disease at diagnosis.
The Houston Methodist researchers are studying similar nanofluidic delivery technology on the International Space Station. Grattoni’s nanomedicine lab at Houston Methodist focuses on implantable nanofluidics-based platforms for controlled and long-term drug delivery and cell transplantation to treat chronic diseases.
Immunotherapy holds promise in treating cancers that previously did not have good treatment options. However, because immunotherapy is delivered throughout the entire body, it causes many side effects that are sometimes long-lasting, if not life-long. By focusing the delivery directly into the tumor, the body is protected from being exposed to toxic drugs and fewer side effects, essentially allowing patients undergoing treatment to have a better quality of life.
“Our goal is to transform the way cancer is treated. We see this device as a viable approach to penetrating the pancreatic tumor in a minimally invasive and effective manner, allowing for a more focused therapy using less medication,” said Alessandro Grattoni, Ph.D., co-corresponding author and chair of the Department of Nanomedicine at Houston Methodist Research Institute.
The NDES device consists of a stainless-steel drug reservoir containing nanochannels, thus creating a membrane that allows for sustained diffusion when the drug is released.
Other medical technology companies offer intratumoral drug-eluting implants for cancer therapeutics, but those are intended for shorter duration use. The Houston Methodist nanofluidic device is intended for long-term controlled and sustained release, avoiding repeated systemic treatment that often leads to adverse side effects.
Additional lab research is underway to determine the effectiveness and safety of this delivery technology, but researchers would like to see this become a viable option for cancer patients in the next five years.
Original Article: IMPLANTABLE DEVICE SHRINKS PANCREATIC TUMORS
More from: Houston Methodist Hospital
The Latest Updates from Bing News
Go deeper with Bing News on:
Intratumoral immunotherapy
- AUA 2024: Back to Medical School: Immunology in NMIBC and Neoadjuvant MIBC for the Urologist
Written by: Julian Chavarriaga, MD - Society of Urologic Oncology (SUO) Clinical Fellow at The University of Toronto, @chavarriagaj on Twitter during the 2024 American Urological Association (AUA) ...
- Supercharging immune cells to battle blood cancer: Advances in cancer immunotherapy
The research suggests that targeting CD300A could be a promising addition to immune checkpoint-based cancer immunotherapy ... with shorter survival and a more "exhausted" phenotype of intratumoral NK ...
- Supercharging immune cells to battle blood cancer: Breakthrough in cancer immunotherapy
A new study reveals a groundbreaking approach to immunotherapy, demonstrating that blocking the interaction between the CD300A receptor and phosphatidylserine (PS) significantly enhances the ability ...
- Can Vitamin D Improve Cancer Immunotherapy?
Your diet could impact your cancer treatment’s progress; a new preclinical study suggests more vitamin D could improve responses to checkpoint inhibitors.
- Combining the 'best of two worlds' to boost immunotherapy response in mice with breast cancer
A new type of immunotherapy drug appears to be more effective than other approaches at stimulating the immune response, the results of a study published April 19 in Nature Biomedical Engineering show.
Go deeper with Bing News on:
Pancreatic cancer
- USA News Group: Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 17, 2024 /PRNewswire/ -- USA News Group - A new study is bringing hope in the fight against one of the deadliest cancers, revealing a ...
- Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatments
A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough is crucial, as ...
- Gimatecan by Lee’s Pharmaceutical for Metastatic Pancreatic Cancer: Likelihood of Approval
Gimatecan is under clinical development by Lee's Pharmaceutical and currently in Phase II for Metastatic Pancreatic Cancer.
- Blacks Have The Highest Rates of Pancreatic Cancer, But We’re Missing From Pancreatic Cancer Trials
New research from Indiana University shows that Black Americans have higher incidence of pancreatic cancer but aren't receiving enough treatment.
- Ashland man battles stage four pancreatic cancer with family, faith, and local care
Scott Montgomery has had his share of health scares, including surviving an accidental gunshot wound and living for more than a decade with multiple sclerosis.N ...